ClinicalTrials.Veeva

Menu

Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Completed

Conditions

Covid19, Patient Reported Outcome Measures, Quality of Life

Treatments

Other: No intervention. Method study. Psychometric testing

Study type

Observational

Funder types

Other
NETWORK

Identifiers

NCT04740372
REK Norway: 171640

Details and patient eligibility

About

Purpose: to develop an international validated patient-reported outcome measure for COVID-19 patients according to international guidelines.

In this phase III of the project, the preliminary questionnaire of 80 items will be tested. It has been developed based on literature review and interviews with health care professionals and patients (phase I-II).

In Phase III A patients will fill in the questionnaire followed by interviews on relevance, importance and wording of the questionnaire In Phase III B patients will fill in the questionnaire and an debriefing questionnaire. We will do explorative psychometric analyses.

Full description

This project aim to develop an international validated patient-reported outcome measure for COVID-19 patients according to international guidelines. The Phase I and II of this development process have been finalized. Based on a systematic literature review , interviews with 44 health-care professionals and 52 patients in 6-7 countries a final list of 80 questions, the preliminary Oslo COVID-19 QLQ - PW80 ©, is ready to be tested in the current Phase III of the development process.

The objectives of the phase III are:

  • In a limited patient group, to check that the items make sense to the target population, that the phrasing and sequence of questions is acceptable, that there are no missing issues and that none of the questions are confusing and/or offensive (Phase IIIA).
  • In addition, in a larger patient group, to test hypothesized subscales for psychometric properties including reliability, prevalence and variance (e.g. Cronbach's alpha coefficient and correlation-based methods) (Phase IIIB).

The end-product, the international COVID-19- specific questionnaire, will be a psychometrically robust patient-reported outcome measure (PROM) to assess HRQoL in patients with or after COVID-19 disease

Enrollment

371 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with verified SARS-CoV-2 infection (positive test according to local/national standards)
  • Patients with active or previous symptomatic COVID-19 disease
  • In-patients in hospitals and nursing homes or out-patients in hospitals or patients discharged from institutions to their home/covid-19 centres or patients staying at home/covid-19 centres during the course of the disease
  • Patients aged 18 years and older
  • Ability to read and comprehend the process and study documents as judged by the investigator
  • Written informed consent

Exclusion criteria

  • Patients in intensive care units (can be recruited after they have been dismissed)
  • Inability to read and comprehend the process and study documents as judged by the investigator

Trial contacts and locations

1

Loading...

Central trial contact

Cecilie D Amdal, PhD; Kristin Bjordal, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems